EDITORIAL COMMENT
Ventricular arrhythmias and cardiomyopathies: Is life always worth living?
Caterina Bisceglia MD, PhD,
Paolo Della Bella MD,
Corresponding Author
Caterina Bisceglia MD, PhD
Arrhythmia Unit and Electrophysiology Laboratories, San Raffaele Hospital, Milan, Italy
Correspondence
Caterina Bisceglia, MD, PhD, Arrhythmia Unit and Electrophysiology Laboratories, San Raffaele Hospital, Milan 20132, Italy.
Email: [email protected]
Search for more papers by this authorPaolo Della Bella MD
Arrhythmia Unit and Electrophysiology Laboratories, San Raffaele Hospital, Milan, Italy
Search for more papers by this authorCaterina Bisceglia MD, PhD,
Paolo Della Bella MD,
Corresponding Author
Caterina Bisceglia MD, PhD
Arrhythmia Unit and Electrophysiology Laboratories, San Raffaele Hospital, Milan, Italy
Correspondence
Caterina Bisceglia, MD, PhD, Arrhythmia Unit and Electrophysiology Laboratories, San Raffaele Hospital, Milan 20132, Italy.
Email: [email protected]
Search for more papers by this authorPaolo Della Bella MD
Arrhythmia Unit and Electrophysiology Laboratories, San Raffaele Hospital, Milan, Italy
Search for more papers by this authorFirst published: 29 January 2018
No disclosures made.
REFERENCES
- 1Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008; 359: 1009–1017.
- 2Perini AP, Kutyifa V, Veazie P, et al. Effects of implantable cardioverter/defibrillator shock and antitachycardia pacing on anxiety and quality of life: A MADIT-RIT substudy. Am Heart J. 2017; 189: 75–84.
- 3Tung R, Vaseghi M, Frankel DS, et al. Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: An International VT Ablation Center Collaborative Group study. Heart Rhythm. 2015; 12: 1997–2007.
- 4Gula LJ, Doucette S, Leong-Sit P, et al. Quality of life with ablation or medical therapy for ventricular arrhythmias: A substudy of VANISH. J Cardiovasc Electrophysiol. 2018; 29. https://doi.org/10.1111/jce.13419.
- 5Kuck KH, Tilz RR, Deneke T, et al. Impact of substrate modification by catheter ablation on implantable cardioverter-defibrillator interventions in patients with unstable ventricular arrhythmias and coronary artery disease: Results from the multicenter randomized controlled SMS (Substrate Modification Study). Circ Arrhythm Electrophysiol. 2017; 10. https://doi.org/10.1161/CIRCEP.116.004422.
- 6Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med. 2016; 375: 111–121.
- 7Frankel DS, Mountantonakis SE, Robinson MR, Zado ES, Callans DJ, Marchlinski FE. Ventricular tachycardia ablation remains treatment of last resort in structural heart disease: Argument for earlier intervention. J Cardiovasc Electrophysiol. 2011; 22: 1123–1128.
- 8Dinov B, Arya A, Bertagnolli L, et al. Early referral for ablation of scar-related ventricular tachycardia is associated with improved acute and long-term outcomes: Results from the Heart Center of Leipzig ventricular tachycardia registry. Circ Arrhythm Electrophysiol. 2014; 7: 1144–1151.
- 9Santangeli P, Frankel DS, Tung R, et al. Early mortality after catheter ablation of ventricular tachycardia in patients with structural heart disease. J Am Coll Cardiol. 2017; 69: 2105–2115.
- 10Chen J, Todd DM, Proclemer A, et al. Management of patients with ventricular tachycardia in Europe: Results of the European Heart Rhythm Association survey. Europace. 2015; 17: 1294–1249.
- 11Silberbauer J, Oloriz T, Maccabelli G, et al. Noninducibility and late potential abolition: A novel combined prognostic procedural end point for catheter ablation of postinfarction ventricular tachycardia. Circ Arrhythm Electrophysiol. 2014; 7: 424–435.
- 12Oloriz T, Baratto F, Trevisi N, et al. Defining the outcome of ventricular tachycardia ablation: Timing and value of programmed ventricular stimulation. Circ Arrhythm Electrophysiol. Epub ahead of print.
- 13Sokoreli I, de Vries JJ, Pauws SC, Steyerberg EW. Depression and anxiety as predictors of mortality among heart failure patients: Systematic review and meta-analysis. Heart Fail Rev. 2016; 21: 49–63.
- 14Mastenbroek MH, Pedersen SS, van der Tweel I, Doevendans PA, Meine M. Results of ENHANCED implantable cardioverter defibrillator programming to reduce therapies and improve quality of life (from the ENHANCED-ICD Study). Am J Cardiol. 2016; 117: 596–604.
- 15Kloppe A, Proclemer A, Arenal A, et al. Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: Data from the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) trial. Circulation. 2014; 130: 308–314.
